Bocidelpar
 | |
| Clinical data | |
|---|---|
| Other names | ASP-0367; ASP0367; MA-0211; MA0211; MTB-1; MTB1 |
| Routes of administration | Oral[1][2] |
| Drug class | Peroxisome proliferator-activated receptor delta (PPARδ) agonist |
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| PDB ligand | |
| Chemical and physical data | |
| Formula | C25H27F3N2O3 |
| Molar mass | 460.497 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Bocidelpar (INN, USAN; developmental code names ASP-0367, MA-0211, and MTB-1) is a peroxisome proliferator-activated receptor delta (PPARδ) agonist which is or was under development for the treatment of mitochondrial myopathies, myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), Duchenne muscular dystrophy, and metabolic disorders.[1][3][2][4][5] It is taken orally.[1][2]
The clinical pharmacodynamics and pharmacokinetics of bocidelpar have been studied.[4][5]
Bocidelpar was originated by Mitobridge and is under development by Astellas Pharma and Mitobridge.[1][3][2] As of February 2026, bocidelpar is in phase 2/3 clinical trials for mitochondrial myopathies and phase 2 trials for ME/CFS, whereas no recent development has been reported for Duchenne muscular dystrophy or metabolic disorders.[1] However, other sources state that bocidelpar has been discontinued.[3][2] The drug was also under development for the treatment of hypoxia, but development for this indication was discontinued.[1] A phase 2 trial for mitochondrial myopathies was terminated due to lack of effectiveness.[1]
See also
[edit]References
[edit]- 1 2 3 4 5 6 7 "Bocidelpar". AdisInsight. 28 February 2026. Retrieved 17 March 2026.
- 1 2 3 4 5 "Bocidelpar Drug Profile". Ozmosi. 1 January 1900. Retrieved 17 March 2026.
- 1 2 3 "Delving into the Latest Updates on Bocidelpar with Synapse". Synapse. 27 February 2026. Retrieved 17 March 2026.
- 1 2 Ito M, Tauscher-Wisniewski S, Smulders RA, Wojtkowski T, Yamada A, Koibuchi A, et al. (January 2022). "Single- and multiple-dose safety, tolerability, pharmacokinetic, and pharmacodynamic profiles of ASP0367, or bocidelpar sulfate, a novel modulator of peroxisome proliferator-activated receptor delta in healthy adults: Results from a phase 1 study". Muscle & Nerve. 65 (1): 110–120. doi:10.1002/mus.27436. PMC 9298414. PMID 34642949.
- 1 2 Iwai M, Heo N, Hashimoto K, Guro S, Moy S, Spence A, et al. (August 2025). "Pharmacokinetics of Bocidelpar, ASP0367, in Renal and Hepatic Impairment: Results From Two Phase 1 Studies". Clinical and Translational Science. 18 (8) e70310. doi:10.1111/cts.70310. PMC 12315851. PMID 40748778.